C-BOP/BEP Chemotherapy for Metastatic Germ Cell Tumours
Author Information
Author(s): Fosså S D, Paluchowska B, Horwich A, Kaiser G, de Mulder P H M, Koriakine O, van Oosterom A T, de Prijck L, Collette L, de Wit R
Primary Institution: Norwegian Radium Hospital and University of Oslo
Hypothesis
The study aimed to assess the efficacy and toxicity of C-BOP/BEP chemotherapy in patients with intermediate and poor prognosis metastatic germ cell tumours.
Conclusion
C-BOP/BEP chemotherapy demonstrated a 1-year progression-free survival rate of 81.8% and manageable toxicity in patients with high-risk metastatic germ cell tumours.
Supporting Evidence
- 45 out of 66 patients achieved a complete response, indicating the treatment's effectiveness.
- The 1-year progression-free survival rate was 81.8%, exceeding the target of 80%.
- The treatment was well tolerated, with no toxic deaths reported.
- 51 patients experienced at least one episode of grade 3/4 leucopenia.
Takeaway
Doctors tested a new chemotherapy treatment for patients with serious testicular cancer, and it worked well for many of them without causing too much harm.
Methodology
This was a multicentre phase II trial involving 66 eligible patients who received C-BOP/BEP chemotherapy and were monitored for response and survival rates.
Potential Biases
Potential biases may arise from the multicentre nature of the trial and patient selection criteria.
Limitations
The study was limited by its non-randomized design and the relatively small sample size.
Participant Demographics
The study included 65 males and 1 female, with a median age of 29 years.
Statistical Information
Confidence Interval
95% CI: 72.5–91.1%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website